InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (53 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
53
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Gadicke Ansbert, Chairman of the Board. Officer active across 9 companies, notably Werewolf Therapeutics, Inc.. Cumulatively, 60 filings have been published. Split: 0 buy · 53 sells. Total volume traded: €42.1m. History available since 30 April 2021. The latest transaction was filed on 2 December 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Gadicke Ansbert
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations60 total
1,314,262 sharesCommon StockSEC:0001231919-26-000055:0
59,277 shares@ US$0.896.5% of flowCommon StockSEC:0001231919-25-000574:0
60,733 shares@ US$0.987.9% of flowCommon StockSEC:0001231919-25-000564:0
64,331 shares@ US$0.837.7% of flowCommon StockSEC:0001231919-25-000550:0
52,627 shares@ US$0.937.6% of flowCommon StockSEC:0001231919-25-000533:0
90,951 shares@ US$0.9815.1% of flowCommon StockSEC:0001231919-25-000507:0
68,480 shares@ US$1.1115.2% of flowCommon StockSEC:0001231919-25-000459:0
140,488 shares@ US$1.2240.5% of flowCommon StockSEC:0001231919-25-000439:0
86,936 shares@ US$1.4348.9% of flowCommon StockSEC:0001231919-25-000404:0
72,709 shares@ US$1.7296.2% of flowCommon StockSEC:0001231919-25-000373:0
1,031,931 shares@ US$8.0619.7% of flowCommon StockSEC:0001415889-25-013252:0
50,873 shares@ US$0.09100.0% of flowCommon StockSEC:0001415889-25-011569:0
304,001 shares0Common StockSEC:0001209191-23-034336:0
178,269 shares@ US$0.74100.0% of flowCommon StockSEC:0001209191-23-031888:0
3,253,796 shares@ US$4.61100.0% of flowCommon StockSEC:0000899243-22-027167:0
158,579 shares@ US$42.0519.5% of flowCommon StockSEC:0001209191-22-002167:0
29,402 shares@ US$34.683.0% of flowCommon StockSEC:0001209191-21-068406:0
9,809 shares@ US$34.621.0% of flowCommon StockSEC:0001209191-21-067705:0
10,952 shares@ US$35.491.1% of flowCommon StockSEC:0001209191-21-067146:0
15,671 shares0Common StockSEC:0001209191-21-066854:0
14,882 shares@ US$27.531.6% of flowCommon StockSEC:0001209191-21-060722:0
14,260 shares@ US$27.091.5% of flowCommon StockSEC:0001209191-21-060489:0
1,922 shares@ US$27.000.2% of flowCommon StockSEC:0001209191-21-060235:0
11,471 shares@ US$27.001.2% of flowCommon StockSEC:0001209191-21-059421:0
32,154 shares@ US$27.003.3% of flowCommon StockSEC:0001209191-21-058208:0
25 of 60 declarations
About Gadicke Ansbert
GADICKE ANSBERT is Chairman of the Board. He is associated with iTeos Therapeutics, Inc., Repare Therapeutics Inc., Werewolf Therapeutics, Inc., Cullinan Oncology, Inc., Harpoon Therapeutics, Inc. and TCR2 THERAPEUTICS INC. The declarant has 60 filings in total, and across the recent filings available, disposals total 42135682 EUR, from 2021-05-04 to 2026-01-14.
